

Binodh S Desilva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/193213/publications.pdf>

Version: 2024-02-01

65
papers

2,892
citations

304701

22
h-index

168376

53
g-index

74
all docs

74
docs citations

74
times ranked

2562
citing authors

#	ARTICLE	IF	CITATIONS
1	Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. <i>Cancer Cell</i> , 2004, 6, 507-516.	16.8	689
2	Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules. <i>Pharmaceutical Research</i> , 2003, 20, 1885-1900.	3.5	551
3	Key elements of bioanalytical method validation for macromolecules. <i>AAPS Journal</i> , 2007, 9, E156-E163.	4.4	130
4	Workshop Report: Crystal City Vä"Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance. <i>AAPS Journal</i> , 2015, 17, 277-288.	4.4	109
5	Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies. <i>Pharmaceutical Research</i> , 2005, 22, 1425-1431.	3.5	100
6	Fully Validated LC-MS/MS Assay for the Simultaneous Quantitation of Coadministered Therapeutic Antibodies in Cynomolgus Monkey Serum. <i>Analytical Chemistry</i> , 2013, 85, 9859-9867.	6.5	74
7	Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor. <i>AAPS Journal</i> , 2010, 12, 576-585.	4.4	58
8	Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 311-318.	2.8	48
9	2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 Éc;" LBA: immunogenicity, biomarkers and PK assays). <i>Bioanalysis</i> , 2017, 9, 1967-1996.	1.5	47
10	2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 Éc;" hybrid) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.5	45
11	Innovative Use of LC-MS/MS for Simultaneous Quantitation of Neutralizing Antibody, Residual Drug, and Human Immunoglobulin G in Immunogenicity Assay Development. <i>Analytical Chemistry</i> , 2014, 86, 2673-2680.	6.5	38
12	Strategies to minimize variability and bias associated with manual pipetting in ligand binding assays to assure data quality of protein therapeutic quantification. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 623-630.	2.8	36
13	Éc;Fit-for-PurposeÉc;-Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1) Tj ETQq1 1 0.784314 rgBT	4.4	35
14	AntibodyÉc;"drug conjugate bioanalysis using LB-LCÉc;"MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. <i>Bioanalysis</i> , 2016, 8, 1383-1401.	1.5	33
15	An integrated multiplatform bioanalytical strategy for antibodyÉc;"drug conjugates: a novel case study. <i>Bioanalysis</i> , 2015, 7, 1569-1582.	1.5	29
16	Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-Î»-1a and PEG-IFN-Î»2a in naive patients. <i>Bioanalysis</i> , 2015, 7, 1093-1106.	1.5	28
17	Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. <i>Journal of Immunological Methods</i> , 2015, 416, 94-104.	1.4	23
18	Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 1128-1133.	2.8	20

#	ARTICLE	IF	CITATIONS
19	Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2489-2497.	3.3	20
20	Tartrate-resistant acid phosphatase (TRACP 5b): A biomarker of bone resorption rate in support of drug development: Modification, validation and application of the BoneTRAP [®] kit assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 1203-1212.	2.8	19
21	Development and validation of an LC-MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. <i>Bioanalysis</i> , 2014, 6, 2371-2383.	1.5	19
22	Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples. <i>Journal of Immunological Methods</i> , 2015, 416, 124-136.	1.4	17
23	Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing. <i>Journal of Immunological Methods</i> , 2018, 462, 34-41.	1.4	17
24	Development of a Generic Anti-PEG Antibody Assay Using BioScale's Acoustic Membrane MicroParticle Technology. <i>AAPS Journal</i> , 2015, 17, 1511-1516.	4.4	16
25	A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples. <i>Journal of Immunological Methods</i> , 2017, 448, 91-104.	1.4	15
26	Report on the AAPS Immunogenicity Guidance Forum. <i>AAPS Journal</i> , 2019, 21, 55.	4.4	14
27	Experimental and statistical approaches in method cross-validation to support pharmacokinetic decisions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 49, 613-618.	2.8	13
28	A multiplexed immunocapture liquid chromatography tandem mass spectrometry assay for the simultaneous measurement of myostatin and GDF-11 in rat serum using an automated sample preparation platform. <i>Analytica Chimica Acta</i> , 2017, 979, 36-44.	5.4	13
29	Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics. <i>Bioanalysis</i> , 2018, 10, 559-576.	1.5	12
30	Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: Benefits and limitations in assay range. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 626-632.	2.8	11
31	Assessment of Incurred Sample Reanalysis for Macromolecules to Evaluate Bioanalytical Method Robustness: Effects from Imprecision. <i>AAPS Journal</i> , 2011, 13, 291-298.	4.4	11
32	Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay. <i>AAPS Journal</i> , 2015, 17, 976-987.	4.4	11
33	Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 988, 81-87.	2.3	11
34	A strategy for improving comparability across sites for ligand binding assays measuring therapeutic proteins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 729-734.	2.8	10
35	Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples. <i>Bioanalysis</i> , 2015, 7, 1869-1883.	1.5	10
36	Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1. <i>AAPS Journal</i> , 2019, 21, 94.	4.4	10

#	ARTICLE	IF	CITATIONS
37	Solid phase synthesis of bifunctional antibodies. <i>Journal of Immunological Methods</i> , 1995, 188, 9-19.	1.4	9
38	Bioanalytical method requirements and statistical considerations in incurred sample reanalysis for macromolecules. <i>Bioanalysis</i> , 2010, 2, 1587-1596.	1.5	9
39	Bioanalytical considerations in the comparability assessment of biotherapeutics. <i>Bioanalysis</i> , 2011, 3, 613-622.	1.5	9
40	Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab. <i>Bioanalysis</i> , 2018, 10, 1273-1287.	1.5	9
41	Addressing matrix effects in ligand-binding assays through the use of new reagents and technology. <i>Bioanalysis</i> , 2014, 6, 1059-1067.	1.5	8
42	Characterization of labeled reagents in ligand-binding assays by a surface plasmon resonance biosensor. <i>Bioanalysis</i> , 2017, 9, 193-207.	1.5	8
43	Synthesis of Bifunctional Antibodies for Immunoassays. <i>Methods</i> , 2000, 22, 33-43.	3.8	7
44	Laboratory automation of high-quality and efficient ligand-binding assays for biotherapeutic drug development. <i>Bioanalysis</i> , 2013, 5, 1635-1648.	1.5	7
45	Targeting an acid labile aspartylâ€“prolyl amide bond as a viable alternative to trypsin digestion to generate a surrogate peptide for LCâ€“MS/MS analysis. <i>Bioanalysis</i> , 2014, 6, 2985-2998.	1.5	7
46	Bioanalysis of biomarkers for drug development. <i>Bioanalysis</i> , 2012, 4, 2425-2426.	1.5	6
47	Rapid development of multiple â€“fit-for-purposeâ€“™ assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs. <i>Bioanalysis</i> , 2013, 5, 1751-1763.	1.5	6
48	Matrix interference in ligand-binding assays: challenge or solution?. <i>Bioanalysis</i> , 2014, 6, 1029-1031.	1.5	6
49	Biomarker Assay Validation by Mass Spectrometry. <i>AAPS Journal</i> , 2022, 24, 66.	4.4	6
50	Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team. <i>AAPS Journal</i> , 2014, 16, 1159-1161.	4.4	5
51	Development and characterization of a free therapeutic ligand binding assay with assistance from kinetics modeling. <i>Journal of Immunological Methods</i> , 2015, 419, 18-24.	1.4	5
52	Catalytic Antibodies for Complex Reactions Hapten Design and the Importance of Screening for Catalysis in the Generation of Catalytic Antibodies for the NDA/CN Reaction. <i>Applied Biochemistry and Biotechnology</i> , 2000, 83, 195-208.	2.9	4
53	A generic template for automated bioanalytical ligand-binding assays using modular robotic scripts in support of discovery biotherapeutic programs. <i>Bioanalysis</i> , 2013, 5, 1735-1750.	1.5	4
54	Validation of an integrated series of ligand-binding assays for the quantitative determination of antibodyâ€“drug conjugates in biological matrices. <i>Bioanalysis</i> , 2016, 8, 519-531.	1.5	4

#	ARTICLE	IF	CITATIONS
55	Accelerating Regulated Bioanalysis for Biotherapeutics: Case Examples Using a Microfluidic Ligand Binding Assay Platform. AAPS Journal, 2017, 19, 82-91.	4.4	4
56	Immunoaffinity-coupled MS: best of both technologies. Bioanalysis, 2016, 8, 1543-1544.	1.5	3
57	Concerted application of LC-MS and ligand binding assays to better understand exposure of a large molecule drug. Bioanalysis, 2018, 10, 1261-1272.	1.5	3
58	Development of a Cell Culture System To Study Antibody Convection in Tumors. Journal of Pharmaceutical Sciences, 1997, 86, 858-864.	3.3	2
59	Specific Method Validation and Sample Analysis Approaches for Biocomparability Studies of Denosumab Addressing Method and Manufacture Site Changes. AAPS Journal, 2013, 15, 70-77.	4.4	2
60	Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment. AAPS Journal, 2015, 17, 1019-1024.	4.4	2
61	Analytical Considerations for Immunoassays for Macromolecules. , 0, , 573-584.		1
62	Stability assessment in ligand-binding assays: a critical parameter for data integrity. Bioanalysis, 2015, 7, 1315-1317.	1.5	1
63	Ligand Binding Assays in the Regulated Bioanalytical Laboratory. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 177-228.	0.6	1
64	The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360. AAPS PharmSciTech, 2018, 19, 3325-3327.	3.3	0
65	The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360. AAPS Journal, 2019, 21, 2.	4.4	0